{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:54:10Z","timestamp":1788497650395,"version":"build-2803163510"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41585-021-00543-4","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T06:03:07Z","timestamp":1638943387000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Perspectives in primary hyperoxaluria \u2014 historical, current and future clinical interventions"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7650","authenticated-orcid":false,"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall L.","family":"Stoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"543_CR1","first-page":"424","volume":"20","author":"L Lepoutre","year":"1925","unstructured":"Lepoutre, L. Calculs multiples chez un enfant: Infiltration du parenchyme r\u00e9nal par des d\u00e9p\u00f4ts cristallins. J. Urol. 20, 424 (1925).","journal-title":"J. Urol."},{"key":"543_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000086360","volume":"25","author":"JC Lieske","year":"2005","unstructured":"Lieske, J. C. et al. International registry for primary hyperoxaluria. Am. J. Nephrol. 25, 290\u2013296 (2005).","journal-title":"Am. J. Nephrol."},{"key":"543_CR3","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559\u20132570 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"543_CR4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0889-8529(02)00030-0","volume":"31","author":"JR Asplin","year":"2002","unstructured":"Asplin, J. R. Hyperoxaluric calcium nephrolithiasis. Endocrinol. Metab. Clin. North Am. 31, 927\u2013949 (2002).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI63679","volume":"123","author":"SR Mulay","year":"2013","unstructured":"Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J. Clin. Invest. 123, 236\u2013246 (2013).","journal-title":"J. Clin. Invest."},{"key":"543_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543784.2013.741587","volume":"22","author":"BB Beck","year":"2013","unstructured":"Beck, B. B., Hoyer-Kuhn, H., Gobel, H., Habbig, S. & Hoppe, B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin. Invest. Drugs 22, 117\u2013129 (2013).","journal-title":"Expert Opin. Invest. Drugs"},{"key":"543_CR7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0022-5347(01)62363-2","volume":"160","author":"RP Holmes","year":"1998","unstructured":"Holmes, R. P. & Assimos, D. G. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J. Urol. 160, 1617\u20131624 (1998).","journal-title":"J. Urol."},{"key":"543_CR8","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2215\/CJN.02760311","volume":"6","author":"CG Monico","year":"2011","unstructured":"Monico, C. G. et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin. J. Am. Soc. Nephrol. 6, 2289\u20132295 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"543_CR9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/000456329803500114","volume":"35","author":"CF Giafi","year":"1998","unstructured":"Giafi, C. F. & Rumsby, G. Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase\/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. Ann. Clin. Biochem. 35, 104\u2013109 (1998).","journal-title":"Ann. Clin. Biochem."},{"key":"543_CR10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jmb.2006.05.018","volume":"360","author":"MP Booth","year":"2006","unstructured":"Booth, M. P., Conners, R., Rumsby, G. & Brady, R. L. Structural basis of substrate specificity in human glyoxylate reductase\/hydroxypyruvate reductase. J. Mol. Biol. 360, 178\u2013189 (2006).","journal-title":"J. Mol. Biol."},{"key":"543_CR11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00109-012-0930-z","volume":"90","author":"R Belostotsky","year":"2012","unstructured":"Belostotsky, R., Pitt, J. J. & Frishberg, Y. Primary hyperoxaluria type III \u2014 a model for studying perturbations in glyoxylate metabolism. J. Mol. Med. 90, 1497\u20131504 (2012).","journal-title":"J. Mol. Med."},{"key":"543_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1042\/BJ20070637","volume":"408","author":"B Cellini","year":"2007","unstructured":"Cellini, B., Bertoldi, M., Montioli, R., Paiardini, A. & Borri Voltattorni, C. Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. Biochem. J. 408, 39\u201350 (2007).","journal-title":"Biochem. J."},{"key":"543_CR13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bbapap.2005.08.004","volume":"1753","author":"K Mdluli","year":"2005","unstructured":"Mdluli, K., Booth, M. P., Brady, R. L. & Rumsby, G. A preliminary account of the properties of recombinant human glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate, and their potential roles in its metabolism. Biochim. Biophys. Acta 1753, 209\u2013216 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"543_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00240-018-1089-z","volume":"47","author":"M Dindo","year":"2019","unstructured":"Dindo, M. et al. Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis 47, 67\u201378 (2019).","journal-title":"Urolithiasis"},{"issue":"Suppl 8","key":"543_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/10.supp8.3","volume":"10","author":"P Cochat","year":"1995","unstructured":"Cochat, P. et al. Epidemiology of primary hyperoxaluria type 1. Soci\u00e9t\u00e9 de Nephrologie and the Soci\u00e9t\u00e9 de N\u00e9phrologie P\u00e9diatrique. Nephrol. Dial. Transpl. 10 (Suppl 8), 3\u20137 (1995).","journal-title":"Nephrol. Dial. Transpl."},{"key":"543_CR16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ndt\/18.2.273","volume":"18","author":"CS van Woerden","year":"2003","unstructured":"van Woerden, C. S., Groothoff, J. W., Wanders, R. J., Davin, J. C. & Wijburg, F. A. Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol. Dial. Transpl. 18, 273\u2013279 (2003).","journal-title":"Nephrol. Dial. Transpl."},{"key":"543_CR17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","volume":"75","author":"B Hoppe","year":"2009","unstructured":"Hoppe, B., Beck, B. B. & Milliner, D. S. The primary hyperoxalurias. Kidney Int. 75, 1264\u20131271 (2009).","journal-title":"Kidney Int."},{"key":"543_CR18","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","volume":"10","author":"EJ Bergstralh","year":"2010","unstructured":"Bergstralh, E. J. et al. Transplantation outcomes in primary hyperoxaluria. Am. J. Transpl. 10, 2493\u20132501 (2010).","journal-title":"Am. J. Transpl."},{"key":"543_CR19","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","volume":"27","author":"SM van der Hoeven","year":"2012","unstructured":"van der Hoeven, S. M., van Woerden, C. S. & Groothoff, J. W. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol. Dial. Transpl. 27, 3855\u20133862 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"543_CR20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.07430711","volume":"7","author":"J Harambat","year":"2012","unstructured":"Harambat, J. et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin. J. Am. Soc. Nephrol. 7, 458\u2013465 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"543_CR21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9200","volume":"22","author":"DP Cregeen","year":"2003","unstructured":"Cregeen, D. P., Williams, E. L., Hulton, S. & Rumsby, G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum. Mutat. 22, 497 (2003).","journal-title":"Hum. Mutat."},{"key":"543_CR22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/hmg\/8.11.2063","volume":"8","author":"SD Cramer","year":"1999","unstructured":"Cramer, S. D., Ferree, P. M., Lin, K., Milliner, D. S. & Holmes, R. P. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum. Mol. Genet. 8, 2063\u20132069 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"543_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1523-1755.2001.00462.x","volume":"59","author":"DS Milliner","year":"2001","unstructured":"Milliner, D. S., Wilson, D. M. & Smith, L. H. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 59, 31\u201336 (2001).","journal-title":"Kidney Int."},{"key":"543_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s004310050649","volume":"156","author":"MJ Kemper","year":"1997","unstructured":"Kemper, M. J., Conrad, S. & Muller-Wiefel, D. E. Primary hyperoxaluria type 2. Eur. J. Pediatr. 156, 509\u2013512 (1997).","journal-title":"Eur. J. Pediatr."},{"key":"543_CR25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajhg.2010.07.023","volume":"87","author":"R Belostotsky","year":"2010","unstructured":"Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392\u2013399 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"543_CR26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","volume":"100","author":"C Martin-Higueras","year":"2021","unstructured":"Martin-Higueras, C. et al. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 100, 621\u2013635 (2021).","journal-title":"Kidney Int."},{"key":"543_CR27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649\u2013658 (2013).","journal-title":"N. Engl. J. Med."},{"key":"543_CR28","unstructured":"Alnylam Pharmaceuticals. Alnylam receives approval for OXLUMO\u2122 (lumasiran) in the European Union for the treatment of primary hyperoxaluria type 1 in all age groups. BioSpace https:\/\/www.biospace.com\/article\/releases\/alnylam-receives-approval-for-oxlumo-lumasiran-in-the-european-union-for-the-treatment-of-primary-hyperoxaluria-type-1-in-all-age-groups\/ (2020)."},{"key":"543_CR29","unstructured":"FDA News Release. FDA approves first drug to treat rare metabolic disorder. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-rare-metabolic-disorder (2020)."},{"key":"543_CR30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.V1291986","volume":"12","author":"E Leumann","year":"2001","unstructured":"Leumann, E. & Hoppe, B. The primary hyperoxalurias. J. Am. Soc. Nephrol. 12, 1986\u20131993 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"543_CR31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ki.2008.63","volume":"73","author":"P Sikora","year":"2008","unstructured":"Sikora, P. et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int. 73, 1181\u20131186 (2008).","journal-title":"Kidney Int."},{"key":"543_CR32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11255-018-1939-1","volume":"50","author":"R Siener","year":"2018","unstructured":"Siener, R., Hoppe, B., Lohr, P., Muller, S. C. & Latz, S. Metabolic profile and impact of diet in patients with primary hyperoxaluria. Int. Urol. Nephrol. 50, 1583\u20131589 (2018).","journal-title":"Int. Urol. Nephrol."},{"key":"543_CR33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000280885","volume":"38","author":"PC Hallson","year":"1983","unstructured":"Hallson, P. C., Rose, G. A. & Sulaiman, S. Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine. Urol. Int. 38, 179\u2013181 (1983).","journal-title":"Urol. Int."},{"key":"543_CR34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199412083312304","volume":"331","author":"DS Milliner","year":"1994","unstructured":"Milliner, D. S., Eickholt, J. T., Bergstralh, E. J., Wilson, D. M. & Smith, L. H. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N. Engl. J. Med. 331, 1553\u20131558 (1994).","journal-title":"N. Engl. J. Med."},{"key":"543_CR35","first-page":"522","volume":"4","author":"LH Smith Jr","year":"1967","unstructured":"Smith, L. H. Jr & Williams, H. E. Treatment of primary hyperoxaluria. Mod. Treat. 4, 522\u2013530 (1967).","journal-title":"Mod. Treat."},{"key":"543_CR36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2215\/CJN.06820613","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn, H. et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin. J. Am. Soc. Nephrol. 9, 468\u2013477 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"543_CR37","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.bbadis.2013.04.010","volume":"1832","author":"S Fargue","year":"2013","unstructured":"Fargue, S., Rumsby, G. & Danpure, C. J. Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim. Biophys. Acta 1832, 1776\u20131783 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"543_CR38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s004670050145","volume":"10","author":"B Hoppe","year":"1996","unstructured":"Hoppe, B. et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr. Nephrol. 10, 488\u2013492 (1996).","journal-title":"Pediatr. Nephrol."},{"key":"543_CR39","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","volume":"70","author":"F Illies","year":"2006","unstructured":"Illies, F., Bonzel, K. E., Wingen, A. M., Latta, K. & Hoyer, P. F. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 70, 1642\u20131648 (2006).","journal-title":"Kidney Int."},{"key":"543_CR40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/089686089401400117","volume":"14","author":"TE Bunchman","year":"1994","unstructured":"Bunchman, T. E. & Swartz, R. D. Oxalate removal in type I hyperoxaluria or acquired oxalosis using HD and equilibration PD. Perit. Dial. Int. 14, 81\u201384 (1994).","journal-title":"Perit. Dial. Int."},{"key":"543_CR41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.1999.00619.x","volume":"56","author":"P Saborio","year":"1999","unstructured":"Saborio, P. & Scheinman, J. I. Transplantation for primary hyperoxaluria in the United States. Kidney Int. 56, 1094\u20131100 (1999).","journal-title":"Kidney Int."},{"key":"543_CR42","first-page":"S22","volume":"43","author":"M Broyer","year":"1993","unstructured":"Broyer, M., Ehrich, J., Jones, E. & Selwood, N. Five year survival of kidney transplantation in children: data from the European (EDTA-ERA) registry. Kidney Int. Suppl. 43, S22\u2013S25 (1993).","journal-title":"Kidney Int. Suppl."},{"key":"543_CR43","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","volume":"5","author":"A Devresse","year":"2020","unstructured":"Devresse, A., Cochat, P., Godefroid, N. & Kanaan, N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int. Rep. 5, 2136\u20132145 (2020).","journal-title":"Kidney Int. Rep."},{"key":"543_CR44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/archsurg.141.8.735","volume":"141","author":"R Ruiz","year":"2006","unstructured":"Ruiz, R. et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch. Surg. 141, 735\u2013741 (2006). discussion 741\u2013732.","journal-title":"Arch. Surg."},{"key":"543_CR45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jhep.2018.02.004","volume":"69","author":"SK Asrani","year":"2018","unstructured":"Asrani, S. K. et al. Recipient characteristics and morbidity and mortality after liver transplantation. J. Hepatol. 69, 43\u201350 (2018).","journal-title":"J. Hepatol."},{"key":"543_CR46","volume":"7","author":"NN Lam","year":"2020","unstructured":"Lam, N. N. et al. Mortality and morbidity in kidney transplant recipients with a failing graft: a matched cohort study. Can. J. Kidney Health Dis. 7, 2054358120908677 (2020).","journal-title":"Can. J. Kidney Health Dis."},{"key":"543_CR47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mt.2015.224","volume":"24","author":"C Martin-Higueras","year":"2016","unstructured":"Martin-Higueras, C., Luis-Lima, S. & Salido, E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. Mol. Ther. 24, 719\u2013725 (2016).","journal-title":"Mol. Ther."},{"key":"543_CR48","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1107\/S1744309109041670","volume":"65","author":"JM Bourhis","year":"2009","unstructured":"Bourhis, J. M. et al. Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazole. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 65, 1246\u20131253 (2009).","journal-title":"Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun."},{"key":"543_CR49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","volume":"28","author":"A Liebow","year":"2017","unstructured":"Liebow, A. et al. An Investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J. Am. Soc. Nephrol. 28, 494\u2013503 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"543_CR50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid. Ther. 28, 109\u2013118 (2018).","journal-title":"Nucleic Acid. Ther."},{"key":"543_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfaa146.LB002","volume":"35","author":"SF Garrelfs","year":"2020","unstructured":"Garrelfs, S. F. et al. ILLUMINATE-A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1). Nephrol. Dial. Transplant. 35, 1\u201314 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"543_CR52","doi-asserted-by":"crossref","unstructured":"Michael, M. et al. PO1624: ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1) (American Society of Nephrology, 2020).","DOI":"10.1681\/ASN.20203110S1515a"},{"key":"543_CR53","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT04152200 (2021)."},{"key":"543_CR54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2169\/internalmedicine.34.326","volume":"34","author":"Y Takahashi","year":"1995","unstructured":"Takahashi, Y., Miyajima, H. & Kaneko, E. Genetic analysis of a family of lactate dehydrogenase A subunit deficiency. Intern. Med. 34, 326\u2013329 (1995).","journal-title":"Intern. Med."},{"key":"543_CR55","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40265-019-01204-y","volume":"79","author":"JE Frampton","year":"2019","unstructured":"Frampton, J. E. Stiripentol: a review in Dravet syndrome. Drugs 79, 1785\u20131796 (2019).","journal-title":"Drugs"},{"key":"543_CR56","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","volume":"129","author":"M Le Dudal","year":"2019","unstructured":"Le Dudal, M. et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J. Clin. Invest. 129, 2571\u20132577 (2019).","journal-title":"J. Clin. Invest."},{"key":"543_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03819647 (2021)."},{"key":"543_CR58","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","volume":"35","author":"C Kempf","year":"2020","unstructured":"Kempf, C. et al. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatr. Nephrol. 35, 1787\u20131789 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"543_CR59","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","volume":"26","author":"C Lai","year":"2018","unstructured":"Lai, C. et al. Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria. Mol. Ther. 26, 1983\u20131995 (2018).","journal-title":"Mol. Ther."},{"key":"543_CR60","unstructured":"Dicerna Pharmaceuticals. Dicerna receives rare pediatric disease designation from U.S. Food and Drug Administration for Nedosiran for treatment of primary hyperoxaluria. Business Wire https:\/\/www.businesswire.com\/news\/home\/20200618005175\/en (2020)."},{"key":"543_CR61","unstructured":"Hoppe, B. et al TH-PO449: PHYOX: A Safety and Tolerability Study of DCR-PHXC in Primary Hyperoxaluria Types 1 and 2 (American Society of Nephrology, 2019)."},{"key":"543_CR62","unstructured":"Dicerna Pharmaceuticals. Dicerna receives rare pediatric disease designation from U.S. Food and Drug Administration for Nedosiran for treatment of primary hyperoxaluria. Business Wire https:\/\/www.businesswire.com\/news\/home\/20210805006062\/en (2021)."},{"key":"543_CR63","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.urology.2021.03.014","volume":"156","author":"K Shee","year":"2021","unstructured":"Shee, K. et al. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology 156, e147\u2013e149 (2021).","journal-title":"Urology"},{"key":"543_CR64","unstructured":"Chinook Therapeutics. Dicerna receives rare pediatric disease designation from U.S. Food and Drug Administration for nedosiran for treatment of primary hyperoxaluria. GlobeNewswire https:\/\/www.businesswire.com\/news\/home\/20200618005175\/en (2021)."},{"key":"543_CR65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/atm.2016.12.70","volume":"5","author":"M Hatch","year":"2017","unstructured":"Hatch, M. Gut microbiota and oxalate homeostasis. Ann. Transl. Med. 5, 36 (2017).","journal-title":"Ann. Transl. Med."},{"key":"543_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00446731","volume":"141","author":"MJ Allison","year":"1985","unstructured":"Allison, M. J., Dawson, K. A., Mayberry, W. R. & Foss, J. G. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch. Microbiol. 141, 1\u20137 (1985).","journal-title":"Arch. Microbiol."},{"key":"543_CR67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00240-013-0601-8","volume":"41","author":"M Hatch","year":"2013","unstructured":"Hatch, M. & Freel, R. W. A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis 41, 379\u2013384 (2013).","journal-title":"Urolithiasis"},{"key":"543_CR68","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.ki.5001707","volume":"70","author":"B Hoppe","year":"2006","unstructured":"Hoppe, B. et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 70, 1305\u20131311 (2006).","journal-title":"Kidney Int."},{"key":"543_CR69","unstructured":"OxThera. OxThera receives rare pediatric disease designation from U.S. FDA for oxabact treatment of primary hyperoxaluria. OxThera https:\/\/news.cision.com\/oxthera\/r\/oxthera-receives-rare-pediatric-disease-designation-from-u-s-fda-for-oxabact-treatment-of-primary-h (2020)."},{"key":"543_CR70","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00467-016-3553-8","volume":"32","author":"B Hoppe","year":"2017","unstructured":"Hoppe, B. et al. A randomised phase I\/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr. Nephrol. 32, 781\u2013790 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"543_CR71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00240-017-0998-6","volume":"46","author":"D Milliner","year":"2018","unstructured":"Milliner, D., Hoppe, B. & Groothoff, J. A randomised phase II\/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis 46, 313\u2013323 (2018).","journal-title":"Urolithiasis"},{"key":"543_CR72","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03116685 (2021)."},{"key":"543_CR73","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1093\/ndt\/gfr107","volume":"26","author":"B Hoppe","year":"2011","unstructured":"Hoppe, B. et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol. Dial. Transpl. 26, 3609\u20133615 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"543_CR74","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00467-019-04463-9","volume":"35","author":"L Pape","year":"2020","unstructured":"Pape, L., Ahlenstiel-Grunow, T., Birtel, J., Krohne, T. U. & Hoppe, B. Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis. Pediatr. Nephrol. 35, 1121\u20131124 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"543_CR75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00240-015-0845-6","volume":"44","author":"AB Peck","year":"2016","unstructured":"Peck, A. B., Canales, B. K. & Nguyen, C. Q. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease? Urolithiasis 44, 45\u201350 (2016).","journal-title":"Urolithiasis"},{"key":"543_CR76","volume":"7","author":"E Lee","year":"2014","unstructured":"Lee, E., Jeong, B. C., Park, Y. H. & Kim, H. H. Expression of the gene encoding oxalate decarboxylase from Bacillus subtilis and characterization of the recombinant enzyme. BMC Res. Notes 7, 598 (2014).","journal-title":"BMC Res. Notes"},{"key":"543_CR77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.yrtph.2017.03.016","volume":"86","author":"H Cowley","year":"2017","unstructured":"Cowley, H. et al. In vitro and in vivo safety evaluation of Nephure. Regul. Toxicol. Pharmacol. 86, 241\u2013252 (2017).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"543_CR78","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5527\/wjn.v4.i2.235","volume":"4","author":"B Bhasin","year":"2015","unstructured":"Bhasin, B., Urekli, H. M. & Atta, M. G. Primary and secondary hyperoxaluria: understanding the enigma. World J. Nephrol. 4, 235\u2013244 (2015).","journal-title":"World J. Nephrol."},{"key":"543_CR79","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.34067\/KID.0001522020","volume":"1","author":"E Quintero","year":"2020","unstructured":"Quintero, E. et al. A prospective, double-blind, randomized, placebo-controlled, crossover study using an orally administered oxalate decarboxylase (OxDC). Kidney360 1, 1284\u20131290 (2020).","journal-title":"Kidney360"},{"key":"543_CR80","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/end.2012.0214","volume":"27","author":"PW Mufarrij","year":"2013","unstructured":"Mufarrij, P. W., Lange, J. N., Knight, J., Assimos, D. G. & Holmes, R. P. The effects of Oxazyme on oxalate degradation: results and implications of in vitro experiments. J. Endourol. 27, 284\u2013287 (2013).","journal-title":"J. Endourol."},{"key":"543_CR81","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT01127087 (2012)."},{"key":"543_CR82","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000448766","volume":"44","author":"CB Langman","year":"2016","unstructured":"Langman, C. B. et al. A double-blind, placebo controlled, randomized phase 1 cross-over study with ALLN-177, an orally administered oxalate degrading enzyme. Am. J. Nephrol. 44, 150\u2013158 (2016).","journal-title":"Am. J. Nephrol."},{"key":"543_CR83","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11255-019-02098-1","volume":"51","author":"JE Lingeman","year":"2019","unstructured":"Lingeman, J. E. et al. ALLN-177, oral enzyme therapy for hyperoxaluria. Int. Urol. Nephrol. 51, 601\u2013608 (2019).","journal-title":"Int. Urol. Nephrol."},{"key":"543_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03391804 (2020)."},{"key":"543_CR85","doi-asserted-by":"crossref","first-page":"30493","DOI":"10.1074\/jbc.M803525200","volume":"283","author":"ED Hopper","year":"2008","unstructured":"Hopper, E. D., Pittman, A. M., Fitzgerald, M. C. & Tucker, C. L. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase. J. Biol. Chem. 283, 30493\u201330502 (2008).","journal-title":"J. Biol. Chem."},{"key":"543_CR86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071963","volume":"8","author":"N Mesa-Torres","year":"2013","unstructured":"Mesa-Torres, N. et al. The role of protein denaturation energetics and molecular chaperones in the aggregation and mistargeting of mutants causing primary hyperoxaluria type I. PLoS ONE 8, e71963 (2013).","journal-title":"PLoS ONE"},{"key":"543_CR87","first-page":"687658","volume":"2013","author":"AL Pey","year":"2013","unstructured":"Pey, A. L., Albert, A. & Salido, E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. Biomed. Res. Int. 2013, 687658 (2013).","journal-title":"Biomed. Res. Int."},{"key":"543_CR88","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1146\/annurev.biochem.052308.114844","volume":"78","author":"ET Powers","year":"2009","unstructured":"Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W. & Balch, W. E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959\u2013991 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"543_CR89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000085411","volume":"25","author":"CG Monico","year":"2005","unstructured":"Monico, C. G., Olson, J. B. & Milliner, D. S. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am. J. Nephrol. 25, 183\u2013188 (2005).","journal-title":"Am. J. Nephrol."},{"key":"543_CR90","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1523-1755.2004.00796.x","volume":"66","author":"CS van Woerden","year":"2004","unstructured":"van Woerden, C. S. et al. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int. 66, 746\u2013752 (2004).","journal-title":"Kidney Int."},{"key":"543_CR91","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ekir.2020.04.004","volume":"5","author":"P Singh","year":"2020","unstructured":"Singh, P. et al. Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (Atypical) AGXT gene mutation. Kidney Int. Rep. 5, 955\u2013958 (2020).","journal-title":"Kidney Int. Rep."},{"key":"543_CR92","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1523-1755.2005.00267.x","volume":"67","author":"CG Monico","year":"2005","unstructured":"Monico, C. G., Rossetti, S., Olson, J. B. & Milliner, D. S. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 67, 1704\u20131709 (2005).","journal-title":"Kidney Int."},{"key":"543_CR93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-017-0105-8","volume":"41","author":"M Dindo","year":"2018","unstructured":"Dindo, M., Oppici, E., Dell\u2019Orco, D., Montone, R. & Cellini, B. Correlation between the molecular effects of mutations at the dimer interface of alanine-glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6. J. Inherit. Metab. Dis. 41, 263\u2013275 (2018).","journal-title":"J. Inherit. Metab. Dis."},{"key":"543_CR94","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3389\/fimmu.2018.01070","volume":"9","author":"G Zhao","year":"2018","unstructured":"Zhao, G. et al. Betaine in inflammation: mechanistic aspects and applications. Front. Immunol. 9, 1070 (2018).","journal-title":"Front. Immunol."},{"key":"543_CR95","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1073\/pnas.1131968100","volume":"100","author":"A Santana","year":"2003","unstructured":"Santana, A., Salido, E., Torres, A. & Shapiro, L. J. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc. Natl Acad. Sci. USA 100, 7277\u20137282 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"543_CR96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ymgme.2008.03.010","volume":"94","author":"MB Coulter-Mackie","year":"2008","unstructured":"Coulter-Mackie, M. B. & Lian, Q. Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants. Mol. Genet. Metab. 94, 368\u2013374 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"543_CR97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/bj20030371","volume":"374","author":"MJ Lumb","year":"2003","unstructured":"Lumb, M. J., Birdsey, G. M. & Danpure, C. J. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem. J. 374, 79\u201387 (2003).","journal-title":"Biochem. J."},{"key":"543_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT00283387 (2013)."},{"key":"543_CR99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/dmm.013474","volume":"7","author":"JS Valastyan","year":"2014","unstructured":"Valastyan, J. S. & Lindquist, S. Mechanisms of protein-folding diseases at a glance. Dis. Model. Mech. 7, 9\u201314 (2014).","journal-title":"Dis. Model. Mech."},{"key":"543_CR100","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.bbadis.2013.09.002","volume":"1832","author":"E Oppici","year":"2013","unstructured":"Oppici, E., Roncador, A., Montioli, R., Bianconi, S. & Cellini, B. Gly161 mutations associated with primary hyperoxaluria type I induce the cytosolic aggregation and the intracellular degradation of the apo-form of alanine:glyoxylate aminotransferase. Biochim. Biophys. Acta 1832, 2277\u20132288 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"543_CR101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000332398","volume":"73","author":"ER Weissenbacher","year":"2012","unstructured":"Weissenbacher, E. R. et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol. Obstet. Invest. 73, 8\u201315 (2012).","journal-title":"Gynecol. Obstet. Invest."},{"key":"543_CR102","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","volume":"111","author":"N Miyata","year":"2014","unstructured":"Miyata, N. et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc. Natl Acad. Sci. USA 111, 14406\u201314411 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"543_CR103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00109-018-1651-8","volume":"96","author":"R Belostotsky","year":"2018","unstructured":"Belostotsky, R. et al. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. J. Mol. Med. 96, 621\u2013630 (2018).","journal-title":"J. Mol. Med."},{"key":"543_CR104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20140250","volume":"462","author":"N Mesa-Torres","year":"2014","unstructured":"Mesa-Torres, N. et al. The consensus-based approach for gene\/enzyme replacement therapies and crystallization strategies: the case of human alanine-glyoxylate aminotransferase. Biochem. J. 462, 453\u2013463 (2014).","journal-title":"Biochem. J."},{"key":"543_CR105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10989-012-9333-9","volume":"19","author":"A Roncador","year":"2013","unstructured":"Roncador, A., Oppici, E., Montioli, R., Maset, F. & Cellini, B. TAT-mediated delivery of human alanine:glyoxylate aminotransferase in a cellular model of primary hyperoxaluria type I. Int. J. Pept. Res. Ther. 19, 175\u2013184 (2013).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"543_CR106","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nano.2016.12.011","volume":"13","author":"A Roncador","year":"2017","unstructured":"Roncador, A. et al. Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I. Nanomedicine 13, 897\u2013907 (2017).","journal-title":"Nanomedicine"},{"key":"543_CR107","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/nat.2018.0740","volume":"29","author":"A Kukreja","year":"2019","unstructured":"Kukreja, A. et al. Systemic alanine glyoxylate aminotransferase mRNA improves glyoxylate metabolism in a mouse model of primary hyperoxaluria type 1. Nucleic Acid. Ther. 29, 104\u2013113 (2019).","journal-title":"Nucleic Acid. Ther."},{"key":"543_CR108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","volume":"23","author":"R Castello","year":"2016","unstructured":"Castello, R. et al. Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1. Gene Ther. 23, 129\u2013134 (2016).","journal-title":"Gene Ther."},{"key":"543_CR109","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","volume":"19","author":"E Salido","year":"2011","unstructured":"Salido, E. et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol. Ther. 19, 870\u2013875 (2011).","journal-title":"Mol. Ther."},{"key":"543_CR110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bbrc.2019.07.109","volume":"517","author":"J Esteve","year":"2019","unstructured":"Esteve, J. et al. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR\/Cas9 technology. Biochem. Biophys. Res. Commun. 517, 677\u2013683 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"543_CR111","doi-asserted-by":"crossref","first-page":"101467","DOI":"10.1016\/j.scr.2019.101467","volume":"38","author":"J Esteve","year":"2019","unstructured":"Esteve, J. et al. Generation of induced pluripotent stem cells-derived hepatocyte-like cells for ex vivo gene therapy of primary hyperoxaluria type 1. Stem Cell Res. 38, 101467 (2019).","journal-title":"Stem Cell Res."},{"key":"543_CR112","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/ndt\/gfr776","volume":"27","author":"BB Beck","year":"2012","unstructured":"Beck, B. B. et al. Liver cell transplantation in severe infantile oxalosis \u2014 a potential bridging procedure to orthotopic liver transplantation? Nephrol. Dial. Transpl. 27, 2984\u20132989 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"543_CR113","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/TP.0b013e31816de49e","volume":"85","author":"J Jiang","year":"2008","unstructured":"Jiang, J. et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 85, 1253\u20131260 (2008).","journal-title":"Transplantation"},{"key":"543_CR114","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S. S. & Chakraborty, C. CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol. Ther. 29, 571\u2013586 (2021).","journal-title":"Mol. Ther."},{"key":"543_CR115","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin, F., Rudin, C. M. & Sen, T. CRISPR gene therapy: applications, limitations, and implications for the future. Front. Oncol. 10, 1387 (2020).","journal-title":"Front. Oncol."},{"key":"543_CR116","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S. & Yang, S. H. Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol. Ther. Nucleic Acids 4, e264 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"543_CR117","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrc3537","volume":"13","author":"SF Bunting","year":"2013","unstructured":"Bunting, S. F. & Nussenzweig, A. End-joining, translocations and cancer. Nat. Rev. Cancer 13, 443\u2013454 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"543_CR118","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543\u2013548 (2015).","journal-title":"Nat. Biotechnol."},{"key":"543_CR119","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1111\/febs.13416","volume":"282","author":"SV Vartak","year":"2015","unstructured":"Vartak, S. V. & Raghavan, S. C. Inhibition of nonhomologous end joining to increase the specificity of CRISPR\/Cas9 genome editing. FEBS J. 282, 4289\u20134294 (2015).","journal-title":"FEBS J."},{"key":"543_CR120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84\u201388 (2016).","journal-title":"Science"},{"key":"543_CR121","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490\u2013495 (2016).","journal-title":"Nature"},{"key":"543_CR122","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12539-018-0298-z","volume":"10","author":"Y Cui","year":"2018","unstructured":"Cui, Y., Xu, J., Cheng, M., Liao, X. & Peng, S. Review of CRISPR\/Cas9 sgRNA Design Tools. Interdiscip. Sci. 10, 455\u2013465 (2018).","journal-title":"Interdiscip. Sci."},{"key":"543_CR123","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/bioinformatics\/btaa041","volume":"36","author":"K Hiranniramol","year":"2020","unstructured":"Hiranniramol, K., Chen, Y., Liu, W. & Wang, X. Generalizable sgRNA design for improved CRISPR\/Cas9 editing efficiency. Bioinformatics 36, 2684\u20132689 (2020).","journal-title":"Bioinformatics"},{"key":"543_CR124","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry, R. J. et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat. Med. 24, 939\u2013946 (2018).","journal-title":"Nat. Med."},{"key":"543_CR125","first-page":"612823","volume":"2014","author":"Z Hu","year":"2014","unstructured":"Hu, Z. et al. Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed. Res. Int. 2014, 612823 (2014).","journal-title":"Biomed. Res. Int."},{"key":"543_CR126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249\u2013254 (2019).","journal-title":"Nat. Med."},{"key":"543_CR127","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","volume":"6","author":"CH Lau","year":"2017","unstructured":"Lau, C. H. & Suh, Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res 6, 2153 (2017).","journal-title":"F1000Res"},{"key":"543_CR128","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/mt.2015.151","volume":"24","author":"T Gaj","year":"2016","unstructured":"Gaj, T., Epstein, B. E. & Schaffer, D. V. Genome engineering using adeno-associated virus: basic and clinical research applications. Mol. Ther. 24, 458\u2013464 (2016).","journal-title":"Mol. Ther."},{"key":"543_CR129","doi-asserted-by":"publisher","DOI":"10.1101\/gr.231936.117","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. https:\/\/doi.org\/10.1101\/gr.231936.117 (2018).","journal-title":"Genome Res."},{"key":"543_CR130","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.4081\/ejh.2019.3048","volume":"63","author":"C Berardo","year":"2019","unstructured":"Berardo, C. et al. Comparison between lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma. Eur. J. Histochem. 63, 3048 (2019).","journal-title":"Eur. J. Histochem."},{"key":"543_CR131","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gr.171264.113","volume":"24","author":"S Ramakrishna","year":"2014","unstructured":"Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020\u20131027 (2014).","journal-title":"Genome Res."},{"key":"543_CR132","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"BH Yip","year":"2020","unstructured":"Yip, B. H. Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules 10, 839 (2020).","journal-title":"Biomolecules"},{"key":"543_CR133","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00467-020-04817-8","volume":"36","author":"R Belostotsky","year":"2021","unstructured":"Belostotsky, R. & Frishberg, Y. Novel therapeutic approaches for the primary hyperoxalurias. Pediatr. Nephrol. 36, 2593\u20132606 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"543_CR134","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07827-1","volume":"9","author":"N Zabaleta","year":"2018","unstructured":"Zabaleta, N. et al. CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat. Commun. 9, 5454 (2018).","journal-title":"Nat. Commun."},{"key":"543_CR135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.kint.2020.04.049","volume":"98","author":"R Zheng","year":"2020","unstructured":"Zheng, R. et al. CRISPR\/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1. Kidney Int. 98, 947\u2013957 (2020).","journal-title":"Kidney Int."},{"key":"543_CR136","volume":"10","author":"R Zheng","year":"2020","unstructured":"Zheng, R. et al. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR\/Cas9 system alleviates primary hyperoxaluria type 1. Clin. Transl. Med. 10, e261 (2020).","journal-title":"Clin. Transl. Med."},{"key":"543_CR137","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada, T. & Muruve, D. A. The role of inflammasomes in kidney disease. Nat. Rev. Nephrol. 15, 501\u2013520 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"543_CR138","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","volume":"93","author":"HJ Anders","year":"2018","unstructured":"Anders, H. J. et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 93, 656\u2013669 (2018).","journal-title":"Kidney Int."},{"key":"543_CR139","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MNH.0000000000000229","volume":"25","author":"T Ermer","year":"2016","unstructured":"Ermer, T., Eckardt, K. U., Aronson, P. S. & Knauf, F. Oxalate, inflammasome, and progression of kidney disease. Curr. Opin. Nephrol. Hypertens. 25, 363\u2013371 (2016).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"543_CR140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"543_CR141","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.2013.207","volume":"84","author":"F Knauf","year":"2013","unstructured":"Knauf, F. et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 84, 895\u2013901 (2013).","journal-title":"Kidney Int."},{"key":"543_CR142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2019.00091","volume":"7","author":"H Wajant","year":"2019","unstructured":"Wajant, H. & Siegmund, D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front. Cell Dev. Biol. 7, 91 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"543_CR143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1681\/ASN.2016040486","volume":"28","author":"SR Mulay","year":"2017","unstructured":"Mulay, S. R. et al. Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J. Am. Soc. Nephrol. 28, 761\u2013768 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"543_CR144","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1084\/jem.20160462","volume":"214","author":"V Neudecker","year":"2017","unstructured":"Neudecker, V. et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J. Exp. Med. 214, 1737\u20131752 (2017).","journal-title":"J. Exp. Med."},{"key":"543_CR145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.kint.2016.03.035","volume":"90","author":"I Ludwig-Portugall","year":"2016","unstructured":"Ludwig-Portugall, I. et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 90, 525\u2013539 (2016).","journal-title":"Kidney Int."},{"key":"543_CR146","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti, C. et al. OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc. Natl Acad. Sci. USA 115, E1530\u2013E1539 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"543_CR147","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kluck","year":"2020","unstructured":"Kluck, V. et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2, e270\u2013e280 (2020).","journal-title":"Lancet Rheumatol."},{"key":"543_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT01768975 (2014)."},{"key":"543_CR149","unstructured":"Sobi North America. FDA Approves KINERET\u00ae (anakinra) for the treatment of deficiency of IL-1 receptor antagonist (DIRA). GlobeNewswire https:\/\/www.globenewswire.com\/news-release\/2020\/12\/22\/2149573\/0\/en\/FDA-Approves-KINERET-anakinra-for-the-Treatment-of-Deficiency-of-IL-1-Receptor-Antagonist-DIRA.html (2020)."},{"key":"543_CR150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou, V. et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 152, 52\u201359 (2016).","journal-title":"JAMA Dermatol."},{"key":"543_CR151","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato, A. et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 316, 1906\u20131912 (2016).","journal-title":"JAMA"},{"key":"543_CR152","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2665-9913(20)30160-0","volume":"2","author":"A King","year":"2020","unstructured":"King, A. et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2, e379\u2013e381 (2020).","journal-title":"Lancet Rheumatol."},{"key":"543_CR153","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJM198504113121504","volume":"312","author":"ER Yendt","year":"1985","unstructured":"Yendt, E. R. & Cohanim, M. Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. N. Engl. J. Med. 312, 953\u2013957 (1985).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00543-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:11:07Z","timestamp":1733893867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1038\/s41585-021-00543-4","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"assertion":[{"value":"8 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}